Cargando…

A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States

Since 2020, the US Preventive Services Taskforce has recommended expanding hepatitis C virus (HCV) screening to include ages 18−79, in addition to baby boomers (born 1945−1965) and those at-risk for hepatitis C virus. This retrospective cohort analysis compared patients (18 years and above) tested f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonas, Mary Cabell, Rubenstein, Kevin, Watson, Eric, Basra, Sundeep, Horberg, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619706/
https://www.ncbi.nlm.nih.gov/pubmed/34834947
http://dx.doi.org/10.3390/v13112140
_version_ 1784605058579562496
author Jonas, Mary Cabell
Rubenstein, Kevin
Watson, Eric
Basra, Sundeep
Horberg, Michael
author_facet Jonas, Mary Cabell
Rubenstein, Kevin
Watson, Eric
Basra, Sundeep
Horberg, Michael
author_sort Jonas, Mary Cabell
collection PubMed
description Since 2020, the US Preventive Services Taskforce has recommended expanding hepatitis C virus (HCV) screening to include ages 18−79, in addition to baby boomers (born 1945−1965) and those at-risk for hepatitis C virus. This retrospective cohort analysis compared patients (18 years and above) tested for HCV through usual care versus a coordinator-supported program (HCV pathway) during 2015−2018 within Kaiser Permanente Mid-Atlantic States (KPMAS). In total, 131,176 patients were tested through the HCV pathway and 128,311 through usual care (non-standardized testing). Of those tested, 1.6% (HCV pathway) and 0.5% (usual care) had chronic HCV. Of those with chronic HCV, more patients tested within the HCV pathway completed hepatic transient elastography (82.6% HCV pathway vs. 45.6% usual care; p < 0.001) and a gastroenterology visit (72.2% HCV pathway vs. 46.5% usual care; p < 0.001), and had filled prescriptions for treatment (56.5% HCV pathway vs. 40.3% usual care; p < 0.001). The median time to complete each step was shorter for those tested through the HCV pathway (hepatic transient elastography (26 vs. 118 days), gastroenterology visit (63 vs. 131 days), and prescription fill (222 vs. 326 days)). More patients tested through a coordinator-supported, standardized testing pathway completed the necessary testing steps, in less time, compared to usual care. These findings may inform institutions seeking to create effective population-wide testing programs for HCV and other conditions.
format Online
Article
Text
id pubmed-8619706
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86197062021-11-27 A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States Jonas, Mary Cabell Rubenstein, Kevin Watson, Eric Basra, Sundeep Horberg, Michael Viruses Article Since 2020, the US Preventive Services Taskforce has recommended expanding hepatitis C virus (HCV) screening to include ages 18−79, in addition to baby boomers (born 1945−1965) and those at-risk for hepatitis C virus. This retrospective cohort analysis compared patients (18 years and above) tested for HCV through usual care versus a coordinator-supported program (HCV pathway) during 2015−2018 within Kaiser Permanente Mid-Atlantic States (KPMAS). In total, 131,176 patients were tested through the HCV pathway and 128,311 through usual care (non-standardized testing). Of those tested, 1.6% (HCV pathway) and 0.5% (usual care) had chronic HCV. Of those with chronic HCV, more patients tested within the HCV pathway completed hepatic transient elastography (82.6% HCV pathway vs. 45.6% usual care; p < 0.001) and a gastroenterology visit (72.2% HCV pathway vs. 46.5% usual care; p < 0.001), and had filled prescriptions for treatment (56.5% HCV pathway vs. 40.3% usual care; p < 0.001). The median time to complete each step was shorter for those tested through the HCV pathway (hepatic transient elastography (26 vs. 118 days), gastroenterology visit (63 vs. 131 days), and prescription fill (222 vs. 326 days)). More patients tested through a coordinator-supported, standardized testing pathway completed the necessary testing steps, in less time, compared to usual care. These findings may inform institutions seeking to create effective population-wide testing programs for HCV and other conditions. MDPI 2021-10-23 /pmc/articles/PMC8619706/ /pubmed/34834947 http://dx.doi.org/10.3390/v13112140 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jonas, Mary Cabell
Rubenstein, Kevin
Watson, Eric
Basra, Sundeep
Horberg, Michael
A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States
title A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States
title_full A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States
title_fullStr A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States
title_full_unstemmed A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States
title_short A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States
title_sort comprehensive coordinator supported hepatitis c virus testing and linkage to treatment program at kaiser permanente mid-atlantic states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619706/
https://www.ncbi.nlm.nih.gov/pubmed/34834947
http://dx.doi.org/10.3390/v13112140
work_keys_str_mv AT jonasmarycabell acomprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT rubensteinkevin acomprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT watsoneric acomprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT basrasundeep acomprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT horbergmichael acomprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT jonasmarycabell comprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT rubensteinkevin comprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT watsoneric comprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT basrasundeep comprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates
AT horbergmichael comprehensivecoordinatorsupportedhepatitiscvirustestingandlinkagetotreatmentprogramatkaiserpermanentemidatlanticstates